Navigation Links
Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis

- Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 percent in hip fractures

EAST HANOVER, N.J., May 02, 2007 /PRNewswire/ -- A once-yearly treatment of Reclast(R) (zoledronic acid) Injection significantly reduced the incidence of all types of osteoporotic bone fractures over three years in women with postmenopausal osteoporosis. This study, published today in The New England Journal of Medicine, marks the first time that an osteoporosis treatment significantly reduced all types of fractures in a single study.

Reclast is a bisphosphonate, a class of drugs used to treat osteoporosis, the most common metabolic bone disease affecting more than 10 million people in the US(1). An estimated one out of every two women over age 50 will suffer a broken bone in her lifetime (1).

Unlike other bisphosphonate treatments, where women take daily, weekly or monthly doses for postmenopausal osteoporosis, Reclast is given as a once- yearly 15-minute infusion. Reclast is currently under review by the US Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.

"Unfortunately, many patients who are prescribed oral therapies stop treatment or take less than the full dose throughout a full year, which leads to reduced fracture protection," said Dennis Black, Ph.D., the study's lead author and professor of epidemiology and biostatistics at the University of California, San Francisco. "A once-yearly infusion is an exciting potential treatment option because it offers fracture protection for a full year with one dose."

Results from the study show that Reclast reduced the frequency of fractures among the areas of the body that are typically affected by osteoporosis, including the hip, spine, and wrist. Specifically, a 70 percent reduction was achieved in spine fractures. In the same study, the risk of hip fractures, which are associate
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
5. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
6. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
7. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
8. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
9. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
(Date:5/13/2008)...XIENCE V in SPIRIT III Trial Experience Better, Lo...rombosis than Patients T...wswire-FirstCall/ -- Long-term data,presented for ...bott,s U.S.,pivotal trial studying the XIENCE(TM) ...trated that XIENCE V continues to deliver clinical...
(Date:5/13/2008)...ce, May 13 /- NicOx S.A.,(E...c. has initiated the,first in a series of planned ... patients, under the companies, collaborative agre...ertensive agents using NicOx,proprietary technolo...rom,the companies, joint research program, of whic...
(Date:5/12/2008)...ucts Expand Infection Prevention Business, DUBLIN...Health, a,global provider of products and services...h care, today announced it has completed the,acqui...the manufacturer of,infection prevention products ...rep(R) brand products are used widely in U.S. hosp...
(Date:5/12/2008)...wswire-USNewswire/ -- The Alliance for Lupus,Resea...resolution,supporting the goals and ideals of Nati...other,s Day. The resolution, introduced by Senator...lls on all Americans to take the,week of May 11th ... on,women,s health issues, and recognizes the impo...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Cardinal Health Completes Enturia Acquisition 2Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2ETH Zurich researchers develop antibody test 2378 1ETH Zurich researchers develop antibody test 2378 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 1Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 3Covance to Present at Raymond James 29th Annual Institutional Investors Conference 13260 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 2
... HOUSTON, March 20, 2007 - An overexpressed prote...ng forced to devour,themselves, removing one of th...ell growth, researchers at The University of Texas...issue of Molecular,Cancer Research. , The protein ...,TG2, previously has been found by researchers at ...
...Phase 2 Clinical Trials Initiated, CRANBURY, N.J.,...s, a biopharmaceutical company developing small,mo...ones for the,treatment of a range of human genetic...sitive results from its recently completed,Phase 1...rate,AT2101) for Gaucher disease at the of Medica...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 2Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 3
(Date:5/13/2008)...to Serve as Senior Technology Advisor, SALT LAKE ...f Directors,of Sonic Innovations, Inc. (Nasdaq: S...ing aids, today announced that Andrew Raguskus has...us will continue as a member of the,Board of Direc...s a result,of Mr. Raguskus, announcement, the Boar...
(Date:5/13/2008)...NASDAQ: CRME TSX: COM, VANCOUVER, May 13 /PRNewsw...ME / TSX: COM) today reported financial results fo... unless specified otherwise, are,expressed in Cana...ally,Accepted Accounting Principles (Canadian GAAP...hange rate was CAD$1.00=US$0.9742., Results of Op...
(Date:5/13/2008)...itals that treat the poor from improving, study fi... -- The quality of care at hospitals that treat po...et hospitals, is lagging well behind hospitals tha..., These hospitals, which rely on state and fede...t have the money to improve the quality of care at...
(Date:5/13/2008)...y research could slow to a crawl unless regulators...researchers assert in an upcoming opinion piece. ,...fety research. It just isnt the right fit, says Na... at the Johns Hopkins Berman Institute of Bioethic...lished in the June issue of The Joint Commission J...
Breaking Medicine News(10 mins):Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 2Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 3Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Cardiome Reports First Quarter Results 5Health News:Quality Lags at Safety-Net Hospitals 2Health News:Quality Lags at Safety-Net Hospitals 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3
...MRI in surgical decision-making minimizes the pote...providing a new level of capability to predict sur...ngth. A 3-Tesla is one of the strongest commercial...hysicians describe a case study of five patients. ...
...was never known to be good. And the list of harmfu...ing. A school of thought, courtesy- research from ...o Clinic, has revealed the heightened risk of cart... pain in men who smoke, and suffer knee osteoarthr...
... A perceptive survey has established the prevaili...table on healthy diets, for quick fix snack option...ucted an elaborate nutrition survey which revealed...ong from a tender age. Parents and kids must know...
...easing number of tuberculosis cases detected annua...vernment, the Nation reports.// According to Somc...e Department of Disease Control, TB cases have inc...h officials' efforts. TB incidence in Thailand is ...
Other Medicine News:Health News:A New Technology for Safe Tumor Surgery 2
CYSTOSCOPY "T". DRAPE
NEAR-SkinTM Incise Drape Aggressive adhesive with no residue High moisture permeability for extended adhesion Low-glare matte finish film Product number identification
...ape made of 3M Steri-Drape Absorbent Prevention Fa...xit port. It also includes a finger cot. 64 inche...Abdominal adhesive aperture, Elastic aperture, Neo...er and exit port; Arm Extension 60 inches (152cm),...
The Model 240-A is designed for use in sex offender testing (penile tumescence monitoring). This instrument has an analog output that is optically coupled. This allows the connection of line-powere
Medicine Products: